| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5605147 | International Journal of Cardiology | 2017 | 23 Pages |
Abstract
Indirect comparisons generated the hypothesis that Apixaban and Edoxaban High-Dose might be more likely associated with a better net clinical profile in AF patients with moderate CKD. These findings may potentially guide physicians in selecting the most appropriate NOAC for each patient, while waiting for dedicated evidences.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Giuseppe Andò, Piera Capranzano,